Close

Curexo Technology announces 510(k) submission for total knee arthroplasty application

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...

Thermo Fisher Receives FDA Approval for...

The world leader when it comes to serving science,...

Virtual MRI Imaging with AI Aids...

During the magnetic resonance imaging (MRI) procedures, contrast agents...

CUREXO Technology Corporation, pioneer in medical robotics and world leader in image-directed robotic products for orthopaedic applications, which is focused on marketing its robotic system, announced that it has submitted a premarket notification 510(k) application to the U.S. Food and Drug Administration (FDA) for market clearance in the U.S. for use of its ROBODOC® Surgical System for Total Knee Arthroplasty (TKA).

The 510(k) application is used when there exist similar, previously-cleared technologies in the marketplace. This submission follows the company’s recently cleared 510(k) for Total Hip Arthroplasty (THA) and will offer surgeons an accurate, precise, and reproducible surgical technique to prepare the joint during a knee replacement procedure. The process will allow surgeons to preoperatively plan their surgery in a 3-D virtual space and then execute the surgery exactly as planned in the operating theatre.

Brent D. Mittelstadt, President and CEO of CUREXO Technology Corporation said, We are very pleased to announce the submission of the TKA 510(k) application to the FDA, as it demonstrates that we are moving forward with achieving our goals of providing a world class multi-platform technology,” said Brent D. Mittelstadt, President and CEO of CUREXO Technology Corporation.

Latest stories

Related stories

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Virtual MRI Imaging with AI Aids Better Tumor Detection

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back